Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
A year after Big Pharma’s pull-back from the UK, what’s changed?
A year on from Big Pharma's protest at U.K. drug pricing policy, Fierce reached out to the companies involved to see if they've softened their stance.
James Waldron
Sep 4, 2026 10:00am
The GLP-like race to keep us awake and make billions doing it
Aug 31, 2026 11:24am
Lilly inks $2.88B Merida buyout to expand autoimmune pipeline
Aug 31, 2026 9:18am
Roche, Eli Lilly net FDA approval for Alzheimer’s biomarker test
Aug 24, 2026 8:15am
Lilly pens deal with Gateway Labs resident for RNA vax platform
Aug 20, 2026 10:45am
Lilly pens $370M deal with OmniAb for ion channel collab
Aug 17, 2026 7:43am